Registry finds semaglutide discussed in 93% of HFpEF patients, started by 16%

The wire

1. 01In a retrospective review of 159 registry patients with HFpEF and obesity, semaglutide was discussed or offered to 148 (93.1%), but newly recorded in only 23 of 148 baseline nonusers (15.5%).
2. 02Recorded diabetes or prediabetes was associated with later use (adjusted odds ratio 3.76, 95% CI 1.08-19.93), suggesting coverage and comorbidity status drive who actually starts therapy.
3. 03Authors say the data identify a care gap without establishing causes or verifying initiation; a sensitivity analysis using glycated haemoglobin was inconclusive and the sample is small.

From the source

Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use

Cardiology · 2026 Oct 12 · Jurin I, Jakljevic T et al.